Efficient and Scalable Enantioselective Synthesis of a Key Intermediate for Rimegepant: An Oral CGRP Receptor Antagonist
Pharmaceutical Fronts · 01.03.2024 · 06 (01) · e62-e68
DOI: 10.1055/s-0044-1780495 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutical Fronts, erschienen am 01.03.2024. Verfasst von Zhonghua Luo und 5 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Rimegepant is a calcitonin gene-related peptide antagonist used for acute treatment and prevention of migraine. We herein attempt to explore an efficient and practiced method for scale-up, regio- and enantioselective synthesis of (R)-9-hydroxy-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-5-one (1), a key intermediate of rimegepant. In this work, a Ru-catalyzed asymmetric transfer hydrogenation (ATH) reaction was a key step. The optimization of the reaction conditions involved exploring the reaction parameters including catalysts, bases, and solvents. The results suggested that the Ru-catalyzed ATH process using formic acid as the hydrogen donor could be operated under mild conditions at a low catalyst loading (0.5 mol%), affording a high yield (92.1% yield with 99.8% purity) and gratifying enantioselectivity (99.9% ee) of the target product (1). This work first reported the Ru-catalyzed ATH process in the synthesis of key intermediates of rimegepant. The optimized ATH process was easy to implement and cost-effective, making it particularly suitable for manufacturing scale production.
Zitieren
APA
Luo, Z., Sun, G., Wang, G., Zhang, X., Zhang, Y., & Zhang, J. (2024). Efficient and Scalable Enantioselective Synthesis of a Key Intermediate for Rimegepant: An Oral CGRP Receptor Antagonist. Pharmaceutical Fronts, 06(01), e62-e68. https://doi.org/10.1055/s-0044-1780495
Vancouver
Luo Z, Sun G, Wang G, Zhang X, Zhang Y, Zhang J. Efficient and Scalable Enantioselective Synthesis of a Key Intermediate for Rimegepant: An Oral CGRP Receptor Antagonist. Pharmaceutical Fronts. 2024;06(01):e62-e68. doi:10.1055/s-0044-1780495
BibTeX
@article{Luo2024,
author = {Luo, Zhonghua and Sun, Guodong and Wang, Guowei and Zhang, Xin and Zhang, Yang and Zhang, Ji},
title = {Efficient and Scalable Enantioselective Synthesis of a Key Intermediate for Rimegepant: An Oral CGRP Receptor Antagonist},
journal = {Pharmaceutical Fronts},
year = {2024},
volume = {06},
number = {01},
pages = {e62--e68},
doi = {10.1055/s-0044-1780495}
}
EUVIMED